Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 145

Sort by

Sort Order Select

Journal Articles

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation

Courtney D. DiNardo, Kelly S. Chien, Jillian Mullin, Danielle Hammond, Jeremy Ramdial, Tapan M. Kadia, Fadi G. Haddad, Musa Yilmaz, Koji Sasaki, Ghayas C. Issa, Koichi Takahashi, Elizabeth J. Shpall, Farhad Ravandi, Naval Daver, Hagop Kantarjian

Blood (2024) 144 (Supplement 1): 1527.2.

https://doi.org/10.1182/blood-2024-208771

Published: 2024

Journal Articles

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Blood (2024) 144 (Supplement 1): 6126.

https://doi.org/10.1182/blood-2024-207413

Published: 2024

Journal Articles

Causes of Death in Patients with Myelodysplastic Syndrome and Spliceosome Mutations

Arjun S. Peddireddy, Panayiotis Kontoyiannis, Koji Sasaki, Kelly S. Chien, Jayastu Senapati, Guillermo Montalban-Bravo, Courtney D. DiNardo, Gautam Borthakur, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia-Manero, Samuel Urrutia

Blood (2024) 144 (Supplement 1): 6704.

https://doi.org/10.1182/blood-2024-202540

Published: 2024

Journal Articles

Survival Benefits of Complete Cytogenetic Response in Patients with Newly Diagnosed Myelodysplastic Syndrome

Roberta Santos Azevedo, Hagop M. Kantarjian, Elias Jabbour, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle Hammond, Samuel Urrutia, Carlos E. Bueso-Ramos, Keyur P. Patel, Guillermo Montalban-Bravo, Nicholas J. Short, Naval Daver, Gautam Borthakur, Tapan M. Kadia, William G. Wierda, Guillermo Garcia-Manero, Koji Sasaki

Blood (2024) 144 (Supplement 1): 6727.

https://doi.org/10.1182/blood-2024-201864

Published: 2024

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Journal Articles

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 3204.

https://doi.org/10.1182/blood-2024-208890

Published: 2024

Journal Articles

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Emmanuel Almanza, Wei-Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Danielle Hammond, Yesid Alvarado Valero, Naveen Pemmaraju, Lucia Masarova, Sherry Pierce, Naval Daver, Alex Bataller, Guillermo Garcia-Manero, Amin M. Alousi, Nicholas J. Short, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 1511.

https://doi.org/10.1182/blood-2024-209558

Published: 2024

Journal Articles

Application of Next-Generation Cytogenetics in a Clinical Laboratory for Diagnostic Work-up of Myelodysplastic Syndromes/Neoplasms (MDS)

Anindita Ghosh, Guilin Tang, Hui Yang, Koji Sasaki, Gokce A. Toruner, Juan Jose Rodriguez-Sevilla, Raja Luthra, Danielle Hammond, L. Jeffrey Medeiros, Carlos E. Bueso-Ramos, Guillermo Montalban-Bravo, Kelly S. Chien, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna

Blood (2024) 144 (Supplement 1): 7519.

https://doi.org/10.1182/blood-2024-211967

Published: 2024

Journal Articles

Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes

Mehmet Sevki Uyanik, Guillermo Garcia-Manero, Abhishek Maiti, Farhad Ravandi, Kelly S. Chien, Danielle Hammond, Alexandre Bazinet, Heather Schneider, Stephany Hendrickson, Sherry Pierce, Hagop M. Kantarjian, Naveen Pemmaraju, Guillermo Montalban-Bravo

Blood (2024) 144 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2024-207503

Published: 2024

Journal Articles

A Single-Cell T-Cell Reference Map Delineates the Biological Landscape of CD4 + T Cells in Myelodysplastic Syndromes Under Venetoclax Therapy

Juan Jose Rodriguez Sevilla, Yang Liu, Irene Ganan-Gomez, Vera Adema, Kelly S. Chien, Guillermo Montalban-Bravo, Natthakan Thongon, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna, Sanam Loghavi, Hui Yang, Linghua Wang, Simona Colla

Blood (2024) 144 (Supplement 1): 50.

https://doi.org/10.1182/blood-2024-202641

Published: 2024

Journal Articles

Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse

Nicholas J. Short, Hagop Kantarjian, Nitin Jain, Koichi Takahashi, Ken Furudate, Jayastu Senapati, Fadi G. Haddad, Omer Karrar, Tapan M. Kadia, Kelly S. Chien, Koji Sasaki, Eitan Kugler, Rebecca Garris, Farhad Ravandi, Elias Jabbour

Blood (2024) 144 (Supplement 1): 837.

https://doi.org/10.1182/blood-2024-206602

Published: 2024

Journal Articles

Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)

Anuya A. Natu, Clifford M. Csizmar, Terra L. Lasho, Rashmi Kanagal-Shamanna, Sanam Loghavi, Alexandre Bazinet, Kelly S. Chien, Danielle Hammond, Christy Finke, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Abhishek A. Mangaonkar, Antoine N. Saliba, Ayalew Tefferi, Guillermo Garcia-Manero, Hagop Kantarjian, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 4593.

https://doi.org/10.1182/blood-2024-209236

Published: 2024

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Blood (2024) 144 (Supplement 1): 4584.

https://doi.org/10.1182/blood-2024-210646

Published: 2024

Journal Articles

A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia

Hannah Goulart, Hagop M. Kantarjian, Naval Daver, Musa Yilmaz, Guillermo Garcia-Manero, Kelly S. Chien, Jan A. Burger, Naveen Pemmaraju, Courtney D. DiNardo, Nicholas J. Short, Guillermo Montalban-Bravo, Abhishek Maiti, Danielle Hammond, Ghayas C. Issa, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 2901.

https://doi.org/10.1182/blood-2024-205340

Published: 2024

Journal Articles

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy

Blood (2024) 144 (Supplement 1): 2896.

https://doi.org/10.1182/blood-2024-198541

Published: 2024

Journal Articles

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH -Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials

Blood (2024) 144 (Supplement 1): 2883.

https://doi.org/10.1182/blood-2024-200387

Published: 2024

Journal Articles

Comparative Analysis of Oligomonocytic CMML with Myelodysplastic and Myeloproliferative CMML Subtypes: A Study of 849 Molecularly-Annotated Patients

Clifford M. Csizmar, Anuya A. Natu, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle Hammond, Sanam Loghavi, Alexandre Bazinet, Terra L. Lasho, Christy Finke, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Abhishek A. Mangaonkar, Antoine N. Saliba, Ayalew Tefferi, Guillermo Garcia-Manero, Hagop Kantarjian, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 6747.

https://doi.org/10.1182/blood-2024-209126

Published: 2024

Journal Articles

Characteristics and Survival Outcome of Patients with Isolated 11q Deletion Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 6746.

https://doi.org/10.1182/blood-2024-208444

Published: 2024

Journal Articles

CDC2-like Kinases (CLKs) Inhibition As a Novel Targeted Therapeutic Strategy in Myelodysplastic Syndromes (MDS)

Hui Yang, Zhihong Fang, Yue Wei, Juan Jose Rodriguez Sevilla, Marcos Estecio, Guillermo Montalban-Bravo, Kelly S. Chien, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 6691.

https://doi.org/10.1182/blood-2024-207573

Published: 2024

Journal Articles

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood (2024) 144 (Supplement 1): 1855.

https://doi.org/10.1182/blood-2024-211110

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Causes of Death in Patients with Myelodysplastic Syndrome and Spliceosome Mutations

Survival Benefits of Complete Cytogenetic Response in Patients with Newly Diagnosed Myelodysplastic Syndrome

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Application of Next-Generation Cytogenetics in a Clinical Laboratory for Diagnostic Work-up of Myelodysplastic Syndromes/Neoplasms (MDS)

Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes

A Single-Cell T-Cell Reference Map Delineates the Biological Landscape of CD4 + T Cells in Myelodysplastic Syndromes Under Venetoclax Therapy

Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse

Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH -Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials

Comparative Analysis of Oligomonocytic CMML with Myelodysplastic and Myeloproliferative CMML Subtypes: A Study of 849 Molecularly-Annotated Patients

Characteristics and Survival Outcome of Patients with Isolated 11q Deletion Myelodysplastic Syndromes

CDC2-like Kinases (CLKs) Inhibition As a Novel Targeted Therapeutic Strategy in Myelodysplastic Syndromes (MDS)

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only